GlassScriptPhysician profile
Laura W Goff
NPI 1023165909
$22,113.89
in general payments reported to CMS, 2019-2025
14 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $177 · 2021: $7,720 · 2022: $1,575 · 2023: $55.44 · 2024: $11K · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,440 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,100 · Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,440.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,100.00 |
| Food and Beverage | $101.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $7,600.00 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $4,800.00 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,399.10 | 2020-2024 | |
| Genentech USA, INC. | $1,830.00 | 2021 | |
| Exelixis INC. | $1,650.00 | 2021 | |
| Boehringer Ingelheim International Gmbh | $1,575.00 | 2022 | |
| Glaxosmithkline, LLC. | $158.15 | 2020 | |
| Array Biopharma INC | $55.44 | 2023 | Braftovi |
| Jazz Pharmaceuticals INC. | $46.20 | 2024 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.